Cullinan Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
CGEM$11.23-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(119,928) | $(129,538) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Equity-based compensation expense | 28,190 | 22,919 |
| Accretion on marketable securities | (11,958) | (6,533) |
| Depreciation and amortization | 229 | 233 |
| Impairment of long-lived assets | — | 440 |
| Realized gain on marketable securities | — | (20) |
| Non-cash contributions from noncontrolling interests | — | 4 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (837) | (2,650) |
| Accounts payable | (378) | (1,709) |
| Accrued expenses and other current liabilities | (3,995) | 4,992 |
| Income tax payable | — | (4,282) |
| Net cash used in operating activities | (108,677) | (116,144) |
| Investing activities: | ||
| Purchase of marketable securities | (553,095) | (307,371) |
| Maturities of marketable securities | 400,817 | 291,915 |
| Purchase of property and equipment | — | (208) |
| Net cash used in investing activities | (152,278) | (15,664) |
| Financing activities: | ||
| Issuance of common stock and pre-funded warrants, net of issuance costs | 262,652 | 38,388 |
| Net issuance of common stock under equity-based compensation plans | 6,402 | 290 |
| Acquisition of noncontrolling interests | (4,448) | — |
| Issuance of convertible notes | — | 1,825 |
| Net cash provided by financing activities | 264,606 | 40,503 |
| Net increase (decrease) in cash and cash equivalents | 3,651 | (91,305) |
| Cash and cash equivalents at beginning of period | 98,434 | 156,152 |
| Cash and cash equivalents at end of period | $102,085 | $64,847 |
| SUPPLEMENTAL NONCASH DISCLOSURE | ||
| Non-cash investing and financing activities and supplemental cash flow information | ||
| Cash paid (refunded) for income taxes | $(2,274) | $4,708 |
| Conversion of convertible note into noncontrolling interest | $— | $175 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.